Ligand-modified aminobisphosphonate for linking proteins to hydroxyapatite and bone surface

Bioconjugate Chemistry

Volumn 19, Issue 1, 2008, Pages 315-321

  Ehrick, Robin S ^a   Capaccio, Marcello ^a   Puleo, David A ^b   Bachas, Leonidas G ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOTIN; BIOTINYLAMINOMETHYLENEDIPHOSPHONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BOVINE SERUM ALBUMIN; HYDROXYAPATITE; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BIOTINYLATION; CONTROLLED STUDY; COW; DRUG BINDING; DRUG CONJUGATION; DRUG SYNTHESIS; FEMUR; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS;

EID: 38949211069     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc700196q     Document Type: Article

References (34)

1. Kiberstis, P., Smith, O., and Norman, C. (2000) Bone health in the balance. Science 289, 1497.
2. Ducy, P., Schinke, T., and Karsenty, G. (2000) The osteoblast: A sophisticated fibroblast under central surveillance. Science 289, 1501-1504.
3. Teitelbaum, S. L. (2000) Bone resorption by osteoclasts. Science 289, 1504-1508.
4. Rodan, G. A., and Martin, T. J. (2000) Therapeutic approaches to bone diseases. Science 289, 1508-1514.
5. Finkelstein, J. S. (2006) Calcium plus vitamin D for postmenopausal women - bone appetit? N. Engl. J. Med. 354, 750-751.
6. Jackson, R. D., LaCroix, A. Z., Gass, M., Wallace, R. B., Robbins, J., Lewis, C. E., Bassford, T., Beresford, S. A. A., Black, H. R., Blanchette, P., Bonds, D. E., Brunner, R. L., Brzyski, R. G., Caan, B., Cauley, J. A., Chlebowski, R. T., Cummings, S. R., Granek, I., Hays, J., Heiss, G., Hendrix, S. L., Howard, B. V., Hsia, J., Hubbel, F. A., Johnson, K. C., Judd, H., Kotchen, J. M., Kuller, L. H., Langer, R. D., Lasser, N. L., Limacher, M. C., Ludlam, S., Mason, J. E., Margolis, K. L., McGowan, J., Ockene, J. K., O'Sullivan, M. J., Phillips, L., Prentice, R. L., Sarto, G. E., Stefanick, M. L., Van Horn, L., Wactawski-Wende, J., Whitlock, E., Anderson, G. L., Assaf, A. R., and Barad, D. (2006) Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med. 354, 669-683.
7. Fletcher, S. W., and Colditz, G. A. (2002) Failure of estrogen plus progestin therapy for prevention. J. Am. Med. Assoc. 288, 366-368.
8. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., Jackson, R. D., Beresford, S. A. A., Howard, B. V., Johnson, K. C., Kotchen, J. M., and Ockene, J. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J. Am. Med. Assoc. 288, 321-333.
9. Shumaker, S. A., Legault, C., Rapp, S. R., Thai, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., III, B. N. J., Assaf, A. R., Jackson, R. D., Kotchen, J. M., Wassertheil-Smoller, S., and Wactawski-Wende, J. (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in post-menopausal women. J. Am. Med. Assoc. 289, 2651-2662.
10. Cumming, R. G. (1990) Calcium intake and bone mass: A quantitative review of the evidence. Calcif. Tissue Int. 47, 194-201.
11. Shea, B., Wells, G., Cranney, A., Zytaruk, N., Robinson, V., Griffith, L., Ortiz, Z., Peterson, J., Adachi, J., Tugwell, P., and Guyatt, G. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr. Rev. 23, 552-559.
12. Horowitz, M. C. (1993) Cytokines and estrogen in bone: Antiosteoporotic effects. Science 260, 626-621.
13. Sunyer, T., Lewis, J., Collin-Osdoby, P., and Osdoby, P. (1999) Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J. Clin. Invest. 103, 1409-1418.
14. Lin, J. H. (1996) Bisphosphonates: A review of their pharmacokinetic properties. Bone 18, 75-85.
15. Williams, K. R. (2004) The bisphosphonate story: From detergents to bone disease. J. Chem. Educ. 81, 1406-1407.
16. Reszka, A. A., and Rodan, G. A. (2003) Mechanism of action of bisphosphonates. Curr. Osteoporosis Rep. 1, 45-52.
17. Rodan, G. A., and Reszka, A. A. (2002) Bisphosphonate mechanism of action. Curr. Mol. Med. 2, 571-577.
18. Reszka, A. A., Halasy-Nagy, J. M., Masarachia, P. J., and Rodan, G. A. (1999) Bisphosphonates act directly on the osteoclast to induce caspase cleavage of Mst1 kinase during apoptosis. J. Biol. Chem. 274, 34967-34973.
19. Bagi, C. M. (2005) Targeting of therapeutic agents to bone to treat metastatic cancer. Adv. Drug Delivery Rev. 57, 995-1010.
20. Bansal, G., Gittens, S. A., and Uludaǧ, H. (2004) A di(bis-phosphonic acid) for protein coupling and targeting to bone. J. Pharm. Sci. 93, 2788-2799.
21. Frith, J. C., Monkkonen, J., Blackburn, G. M., Russell, R. G. G., and Rogers, M. J. (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β,γ- dichloromethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res. 12, 1358-1367.
22. Green, J. R. (2004) Zoledronic acid: pharmacologic profile of a potent bisphosphonate. J. Organomet. Chem. 690, 2439-2448.
23. Halasy-Nagy, J. M., Rodan, G. A., and Reszka, A. A. (2001) Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29, 553-559.
24. Lipton, A. (2004) Toward new horizons: The future of bisphosphonate therapy. The Oncologist 9, 38-47.
25. Gittens, S. A., Matyas, J. R., Zernicke, R. F., and Uludaǧ, H. (2003) Imparting bone affinity to glycoproteins through the conjugation of bisphosphonates. Pharm. Res. 20, 978-987.
26. Uludaǧ, H., Kousinioris, N., Gao, T., and Kantoci, D. (2000) Bisphosphonate conjugation to proteins as a means to impart bone affinity. Biotechnol. Prog. 16, 258-267.
27. Gittens, S. A., Bagnall, K., Matyas, J. R., Löbenberg, R., Uludaǧ, and H. (2004) Imparting bone mineral affinity to osteogenic proteins through heparin-bisphosphonate conjugates. J. Controlled Release 98, 255-268.
28. Uludaǧ, H., Gao, T., Wohl, G. R., Kantoci, D., and Zernicke, R. F. (2000) Bone affinity of a bisphosphonate-conjugated protein in vivo. Biotechnol. Prog. 16, 1115-1118.
29. Uludaǧ, H., and Yang, J. (2002) Targeting systemically administered proteins to bone by bisphosphonate conjugation. Biotechnol. Prog. 18, 604-611.
30. Kantoci, D., Denike, J. K., and Wechter, W. J. (1996) Synthesis of aminobisphosphonate. Synth. Commun. 26, 2037-2043.
31. Przyjazny, A., and Bachas, L. G. (1991) Competitive-binding approach to liquid chromatographic postcolumn reactions with fluorimetric detection. Anal. Chim. Acta 246, 103-112.
32. Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Guide, S., Wu, W., Mangood, A., Russell, R. G. G., and Ebetino, F. H. (2006) Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38, 617-627.
33. Uludaǧ, H. (2002) Bisphosphonates as a foundation of drug delivery to bone. Curr. Pharm. Des. 8, 1929-1944.
34. Zhang, S., Gangal, G., and Uludaǧ, H. (2007) "Magic bullets" for bone diseases: Progress in rational design of bone-seeking medicinal agents. Chem. Soc. Rev. 36, 507-531.